Compare HTGC & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTGC | ICUI |
|---|---|---|
| Founded | 2003 | 1984 |
| Country | United States | United States |
| Employees | 50 | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | N/A | 1995 |
| Metric | HTGC | ICUI |
|---|---|---|
| Price | $15.60 | $137.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $18.86 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 1.8M | 254.1K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 12.13% | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.20 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $5.24 | $4.46 |
| P/E Ratio | ★ $8.61 | $116.90 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.70 | $107.02 |
| 52 Week High | $19.67 | $160.29 |
| Indicator | HTGC | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | 66.32 |
| Support Level | $15.22 | $115.74 |
| Resistance Level | $15.96 | $153.00 |
| Average True Range (ATR) | 0.31 | 5.28 |
| MACD | -0.05 | 1.96 |
| Stochastic Oscillator | 40.12 | 80.42 |
Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.